Biomarkers in T cell therapy clinical trials
2011
Biomarkers in T Cell Therapy Clinical Trials
publication
Evidence: moderate
Author Information
Author(s): Michael Kalos
Primary Institution: University of Pennsylvania
Hypothesis
What are the relevant biomarkers for evaluating T cell therapy in clinical trials?
Conclusion
Biomarkers play a crucial role in assessing the efficacy and bioactivity of T cell therapies in clinical trials.
Supporting Evidence
- Biomarkers can provide critical insights into the clinical development of candidate products.
- The review highlights the importance of integrating biomarker studies from preclinical to clinical stages.
- Adaptive clinical trial designs depend on robust biomarker studies.
Takeaway
This study talks about how scientists can use special markers to see if T cell treatments for cancer are working well.
Methodology
The review discusses various biomarker studies related to T cell therapy trials, focusing on their roles in evaluating treatment efficacy and bioactivity.
Limitations
The review does not provide specific data or results from clinical trials, focusing instead on the theoretical framework and challenges.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website